Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2025-08-24 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary". It contains detailed financial data for the half-year period, including assets, liabilities, net profit, earnings per share, and shareholder information. It also includes management assurances about the accuracy of the report and mentions that the report is unaudited. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). The document length is about 5096 characters, which is sufficient to contain actual financial data rather than just an announcement or summary. Hence, the classification is IR with high confidence. H1 2025
2025-08-24 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2025年第二次临时股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2025 second extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the shareholders' meeting, confirming compliance with relevant laws and company articles. It does not contain financial statements, earnings data, or management discussion but focuses on the validation of the shareholders' meeting process and voting outcomes. This type of document is a formal legal opinion related to shareholder meeting procedures and voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the best classification is DVA with high confidence.
2025-08-24 Chinese
第四届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the 4th Board of Directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting's attendance, the agenda items discussed, and the voting results. The key agenda items include approval of the 2025 semi-annual report and related financial management reports, but the document itself does not contain the full semi-annual report or detailed financial statements. Instead, it references that the full reports are disclosed separately on the Beijing Stock Exchange information platform. The document is primarily a board meeting resolution announcement rather than the actual interim/quarterly report or financial statements. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2025-08-24 Chinese
2025年半年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use, management, and status of funds raised through a public stock issuance by Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes specifics on the total amount raised, net proceeds, timing of fund receipt, usage of funds in various projects, idle funds management including investment in financial products, and compliance with regulatory requirements. The document references regulatory approvals and audit verification of funds. It is a specialized report focusing on the management and actual use of raised capital, not a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2025-08-24 Chinese
2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 second extraordinary shareholders meeting of Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and votes. The content focuses on the official voting results and decisions made by shareholders during the meeting, rather than presenting financial data or management discussion. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3804 characters, which is sufficient for a full voting results announcement rather than a brief notice. Therefore, the correct classification is DVA with high confidence.
2025-08-24 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2025 年半年度报告" which translates to "2025 Semi-Annual Report" or "Half-Year Report". It contains detailed financial data including income, profit, assets, liabilities, and operational analysis for the period January 1, 2025 to June 30, 2025. The document includes sections such as company overview, accounting data, business overview, financial analysis, and risk disclosures. It explicitly states it is a half-year report and includes comprehensive financial statements and management discussion. The length is about 15,000 characters, indicating a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.